Core Viewpoint - Halozyme Therapeutics (HALO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in stock price movements [4]. Company Performance and Outlook - For the fiscal year ending December 2024, Halozyme Therapeutics is projected to earn $4 per share, reflecting a 44.4% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Halozyme has risen by 2.5%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, suggesting superior potential for market-beating returns [9][10]. - Halozyme's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong likelihood of stock price appreciation in the near term [11].

Core Viewpoint - Halozyme Therapeutics has withdrawn its non-binding proposal to acquire Evotec SE for €11.00 per share, which would have implied a fully diluted equity value of €2.0 billion, due to Evotec's unwillingness to engage in discussions about a potential combination [1][2]. Group 1: Acquisition Proposal - Halozyme's CEO stated that a combination with Evotec would create a leading global pharma services company, benefiting shareholders, patients, and employees [2]. - Despite extensive external diligence and attempts to engage with Evotec's management, Halozyme faced repeated refusals to discuss the potential transaction [3]. - The formal proposal was made to convey strong interest in exploring a transaction, but it became clear that Evotec's boards were not interested in constructive engagement [3]. Group 2: Company Outlook - Halozyme remains focused on improving patient treatment experiences and is confident in its future, with a strategy aimed at achieving 10 approved products with ENHANZE® by 2025 and $1 billion in royalty revenue by 2027 [4]. - The company has reiterated its 2024 revenue guidance of $970-$1,020 million and adjusted EBITDA of $595-$625 million, indicating significant double-digit growth [4]. Group 3: Company Profile - Halozyme is a biopharmaceutical company known for its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of drugs, improving patient experience [5]. - The company has impacted over 800,000 patients through its commercialized products and has partnered with major pharmaceutical companies like Roche, Takeda, and Pfizer [5]. - Halozyme also develops drug-device combination products aimed at enhancing patient comfort and adherence [6].

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style ...

Core Insights - Halozyme Therapeutics (HALO) is currently viewed as a stronger investment option compared to Amicus Therapeutics (FOLD) for those seeking undervalued stocks [1][3][7] Valuation Metrics - HALO has a forward P/E ratio of 10.63, significantly lower than FOLD's forward P/E of 42.62, indicating HALO may be undervalued [5] - The PEG ratio for HALO is 0.37, while FOLD's PEG ratio is 0.94, suggesting HALO has better expected earnings growth relative to its price [5] - HALO's P/B ratio stands at 11.96 compared to FOLD's 16.14, further supporting HALO's valuation advantage [6] Zacks Rank and Value Grades - HALO holds a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook, while FOLD has a Zacks Rank of 3 (Hold) [3][7] - Based on valuation metrics, HALO has earned a Value grade of A, whereas FOLD has a Value grade of D, highlighting HALO's superior value proposition [6]

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologiesWould meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyondAll-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO, Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("H ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry TeamSAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO) ("Evotec") to acquire Evotec for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. T ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been over two years since my previous Halozyme (NASDAQ: HALO ) article , where I discussed Halozyme's acquisition of Antares Pharma for roughly $960M, which was expected to improve their growth trajectory thanks to the addition of Antares Pharma' ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Core Viewpoint - Halozyme Therapeutics, Inc. reported strong third-quarter 2024 results, with adjusted earnings significantly exceeding expectations and a notable increase in total revenues, prompting an upward revision of its financial guidance for the year [1][2]. Financial Performance - Adjusted earnings for Q3 2024 were $1.27 per share, surpassing the Zacks Consensus Estimate of 99 cents and up from 75 cents per share in the same quarter last year [1]. - Total revenues for the third quarter reached $290 million, marking a 34% year-over-year increase and exceeding the Zacks Consensus Estimate of $248 million [1][2]. Revenue Breakdown - Royalty revenues amounted to $155.1 million, a 36% increase from the previous year, driven by strong demand for Phesgo and subcutaneous Darzalex, and exceeded the model estimate of $134.5 million [4]. - Product sales were $86.7 million, nearly matching the previous year's figure and beating the model estimate of $76.7 million [6]. - Revenues from collaborative agreements rose significantly to $48.4 million from $15 million in the prior year [7]. Adjusted EBITDA and Cash Position - Adjusted EBITDA for Q3 was $184 million, reflecting a 60% increase from the prior year [7]. - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $666.3 million, up from $529 million as of June 30, 2024 [7]. 2024 Financial Guidance - Halozyme raised its 2024 revenue guidance to a range of $970 million to $1.02 billion, indicating year-over-year growth of 13% to 22% [8]. - Royalty revenues are now expected to be between $550 million and $565 million, an increase from the previous estimate of $520 million to $555 million [8]. - Collaboration revenues are projected to contribute $130 million to $150 million, while product sales are anticipated to be in the range of $290 million to $305 million for 2024 [9]. - Adjusted EBITDA is expected to be between $595 million and $625 million, representing a growth of 40% to 47% year-over-year [9]. - The company forecasts adjusted earnings per share in the range of $4.00 to $4.20, indicating an improvement of 44% to 52% year-over-year [10].